title: "To switch or not to switch: that is the question"-more than 10% of ratio @ 3 months: how to treat chronic myeloid leukemia patients with this response?
authors.affiliation: Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy. breccia@bce.uniroma1.it
authors.forename: Massimo
authors.initials: M
authors.lastname: Breccia
authors.forename: Giuliana
authors.initials: G
authors.lastname: Alimena
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents